Advances in Immunotherapy for Hepatitis B

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Hepatitis B virus (HBV) is a major cause of global liver disease, potentially leading to cirrhosis and hepatocellular carcinoma (HCC).
• Chronic HBV infection (CHB) is characterized by persistent viral covalently closed circular DNA (cccDNA) and impaired host immune responses.
• Despite effective antiviral therapies, a functional cure for HBV remains elusive due to immune exhaustion and viral evasion mechanisms.

Purpose of the Study:

• To review current knowledge on the immunopathogenesis and immunobiology of HBV infection.
• To analyze the limitations of existing therapeutic strategies in achieving an HBV cure.
• To propose novel therapeutic approaches, including combination therapies and immunotherapies, for HBV clearance.

Main Methods:

• Literature review of immunopathogenic mechanisms in HBV infection.
• Analysis of immune response evasion strategies employed by HBV.
• Evaluation of current and emerging therapeutic interventions for CHB.

Main Results:

• HBV infection involves complex interactions between the virus and both innate and adaptive immune systems.
• Immune exhaustion and viral evasion are key hurdles in eradicating HBV.
• Existing virus-suppressing regimens do not fully restore antiviral immunity needed for a cure.

Conclusions:

• A functional cure for HBV likely requires strategies that enhance the host's antiviral immune response.
• Combination therapies involving new drugs and innovative immunotherapies hold promise for achieving viral clearance.
• Further research into HBV immunobiology is crucial for developing effective curative treatments.